Scientific deep-dive
Protein Targets and the Lab Panel
At least 1.2 g of protein per kg daily, 0.3–0.4 g/kg per meal, and a six-test panel: vitamin D, B12, iron studies, folate, zinc, thiamin. The upper protein target excludes chronic kidney disease.
“Eat more protein and get your bloods done” is the standard advice, and it is useless without numbers. Two 2026 reviews put numbers to it: a floor of 1.2 g protein for every kilogram you weigh, divided so each meal carries its share, plus a six-test laboratory panel.[1][2] What follows is those figures and the one exclusion attached to them.
The protein targets
| Target | Amount |
|---|---|
| Daily intake | ≥1.2 g/kg body weight |
| Upper range, appropriate adults without CKD | up to 1.6 g/kg |
| Per meal | ~0.3–0.4 g/kg |
| Leucine per meal | ~2.5–3 g |
The per-meal figure matters more than people expect. Muscle protein synthesis responds to a threshold dose at a sitting rather than to a daily total, which is why the framework specifies both. On a drug that suppresses appetite, hitting a per-meal target across fewer, smaller meals is genuinely hard — and it is the practical reason protein tends to be the macronutrient that slips.
The laboratory panel
The proposed panel is short and specific: vitamin D, B12, iron studies, folate, zinc and thiamin.[1]
Each is there for a reason connected to how these drugs work rather than to general wellness testing. Reduced intake and reduced dietary diversity affect all of them; nausea and vomiting affect thiamin acutely; and baseline inadequacy is already common in people with obesity before any drug is involved, which the reviews note explicitly.[1][2]
What runs low in practice, with figures from a large dataset, is covered separately in eating too little on a GLP-1. This panel is the counterpart: not what falls, but what to measure.
Six tests. It is a short list precisely so that it gets done.
Energy floors
The same framework proposes pragmatic energy floors — a minimum daily intake below which micronutrient adequacy becomes very difficult regardless of what you choose to eat.[1] That is the conceptual point worth taking even without a specific number: below a certain intake, no amount of good food selection compensates, because there is not enough food.
This is where the appetite suppression that makes the drug work becomes the thing to manage. Appetite is a poor guide to adequacy on these drugs by design, which is the argument for eating to a plan rather than to hunger.
What kind of evidence this is
Both sources are narrative reviews proposing a framework, not randomized trials testing one. The protein targets are guideline-informed extrapolations into a new context rather than figures validated in people taking these drugs.
That is a real limitation and it does not make them useless. There is no trial establishing the right protein intake on a GLP-1, and there may never be one; in its absence, an explicit number derived from established nutrition guidance is more useful than “eat more protein”. Our lean mass article covers the outcome these targets are aimed at, and the one intervention with randomized support behind it: resistance training.
Frequently Asked Questions
References
- 1.Arslan S, et al. Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation Clinical Nutrition ESPEN. 2026. PMID: 42036071.
- 2.Simancas-Racines D, Campuzano-Donoso M, Rossetti G, et al. Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework Obesity Pillars. 2026. PMID: 42382663.
Related research
Nutrition Drinks Alongside a GLP-1
A real-world study associated nutrition drinks with more fat loss and a better fat-to-lean ratio. The strongest effects were among people who complied — which is a compliance finding wearing a product's clothes.
5 min read
Exercise Plus a GLP-1: What Each One Actually Changes
In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise alone did. Both together did most — and the strength result needs reading carefully.
6 min read
Muscle Volume Versus Muscle Function on a GLP-1
Psoas muscle volume fell 9.3% over 24 weeks while chair-rise time and walking speed both edged better. Mass and function moved in opposite directions in the same people — and only one of them is what anybody wants.
6 min read
Bimagrumab Plus Semaglutide: The Muscle Question
The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.
6 min read
Fat-to-Muscle Ratio: Surgery Versus Drugs
The lean-to-fat ratio improved in both groups at 6, 12 and 24 months. Everyone loses lean tissue when losing weight — the question is the mix, and both interventions improved it.
5 min read
Handgrip Strength and Sarcopenic Obesity
Over twelve months on semaglutide, handgrip strength rose 4.5 kg and sarcopenic obesity fell from 49% to 33% — while lean mass declined early then stabilized rather than continuing down.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Strut Health
Semaglutide at $99/month, 48% under the register median
Pricing Compare
Get started →Care Bare Rx
Knowing which pharmacy fills the vial — it names Belmar Pharmacy
Pricing Compare
Get started →Oak
Semaglutide at $119/month, 37% under the register median
Pricing Compare
Get started →